Exelixis, Inc. (NASDAQ:EXEL) insider Michael Morrissey sold 300,000 shares of the stock in a transaction on Thursday, September 14th. The shares were sold at an average price of $26.90, for a total transaction of $8,070,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Exelixis, Inc. (NASDAQ EXEL) opened at 27.57 on Friday. Exelixis, Inc. has a 52 week low of $10.04 and a 52 week high of $29.50. The firm has a market cap of $8.10 billion, a PE ratio of 139.24 and a beta of 1.97. The stock has a 50 day moving average of $27.06 and a 200-day moving average of $23.39.

Exelixis (NASDAQ:EXEL) last announced its earnings results on Wednesday, August 2nd. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.04 by $0.02. The company had revenue of $99.01 million during the quarter, compared to analysts’ expectations of $85.27 million. Exelixis had a net margin of 18.20% and a return on equity of 80.43%. Exelixis’s quarterly revenue was up 173.1% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.15) earnings per share. Analysts expect that Exelixis, Inc. will post $0.27 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Michael Morrissey Sells 300,000 Shares of Exelixis, Inc. (EXEL) Stock” was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this news story on another publication, it was stolen and reposted in violation of United States & international copyright laws. The original version of this news story can be accessed at https://www.dailypolitical.com/2017/09/16/michael-morrissey-sells-300000-shares-of-exelixis-inc-exel-stock.html.

A number of analysts have weighed in on the stock. BidaskClub raised shares of Exelixis from a “buy” rating to a “strong-buy” rating in a report on Friday, August 25th. Royal Bank Of Canada assumed coverage on shares of Exelixis in a report on Thursday. They issued an “outperform” rating and a $32.00 price target for the company. TheStreet raised shares of Exelixis from a “c” rating to a “b-” rating in a report on Monday, August 7th. Cowen and Company reissued an “outperform” rating on shares of Exelixis in a report on Thursday, August 10th. Finally, William Blair reissued an “outperform” rating on shares of Exelixis in a report on Thursday, July 27th. Five investment analysts have rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company. The stock has an average rating of “Buy” and an average target price of $26.51.

Several institutional investors have recently made changes to their positions in EXEL. Nationwide Fund Advisors boosted its position in shares of Exelixis by 61.2% in the first quarter. Nationwide Fund Advisors now owns 284,279 shares of the biotechnology company’s stock valued at $6,160,000 after acquiring an additional 107,889 shares during the period. Strs Ohio boosted its position in shares of Exelixis by 37.8% in the first quarter. Strs Ohio now owns 47,400 shares of the biotechnology company’s stock valued at $1,027,000 after acquiring an additional 13,000 shares during the period. Wells Fargo & Company MN boosted its position in shares of Exelixis by 167.1% in the first quarter. Wells Fargo & Company MN now owns 1,460,194 shares of the biotechnology company’s stock valued at $31,642,000 after acquiring an additional 913,454 shares during the period. Great West Life Assurance Co. Can boosted its position in shares of Exelixis by 26.9% in the first quarter. Great West Life Assurance Co. Can now owns 28,342 shares of the biotechnology company’s stock valued at $613,000 after acquiring an additional 6,000 shares during the period. Finally, Bank of New York Mellon Corp boosted its position in shares of Exelixis by 7.3% in the first quarter. Bank of New York Mellon Corp now owns 1,264,985 shares of the biotechnology company’s stock valued at $27,412,000 after acquiring an additional 86,522 shares during the period. 79.20% of the stock is owned by institutional investors.

Exelixis Company Profile

Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.

Insider Buying and Selling by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.